Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
-
Socié, Gérard (Hôpital Saint-Louis)
;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Barlev, Arie (Atara Biotherapeutics) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Chevallier, Patrice (University Hospital of Nantes) ;
Fagioli, Franca (University of Turin) ;
Guzman-Becerra, Norma (Atara Biotherapeutics) ;
Kumar, Deepali (University Health Network) ;
Ljungman, Per (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Pigneux, Arnaud (Centre Hospitalier Universitaire de Bordeaux) ;
Sadetsky, Natalia (Atara Biotherapeutics) ;
Yáñez San Segundo, Lucrecia (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantabria)) ;
Shadman, Mazyar (Fred Hutchinson Cancer Center) ;
Storek, Jan (University of Calgary) ;
Thirumalai, Dhanalakshmi (Atara Biotherapeutics) ;
Xing, Baodong (Atara Biotherapeutics) ;
Mohty, Mohamad (Sorbonne University) ;
Universitat Autònoma de Barcelona
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
